Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 7/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8128103 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAARCE1GLA | |
| SCHEMBL26836287 | 0.75 | GAA (0.38) | ALDH1A1KDM4EGAARCE1GLA | |
| SCHEMBL7899954 | 0.74 | ALDH1A1 (0.52) | ALDH1A1KDM4EGAARCE1GLA | |
| SCHEMBL25549269 | 0.73 | GAA (0.36) | ALDH1A1KDM4EGAARCE1GLA | |
| SCHEMBL25101338 | 0.73 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAARCE1GLA | |
| SCHEMBL19678269 | 0.72 | POLB (0.37) | ALDH1A1KDM4EGAAGLASMN1; SMN2 | |
| SCHEMBL10406955 | 0.71 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAARCE1GLA | |
| SCHEMBL9555662 | 0.71 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAARCE1GLA | |
| SCHEMBL16419894 | 0.71 | DGAT1 (0.31) | — | |
| SCHEMBL9924211 | 0.71 | DGAT1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| US-10927088-B2 | Thymoquinone derivatives for treatment of cancer | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2021-02-23 | — | — | US | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-20200031789-A1 | Thymoquinone Derivatives for Treatment of Cancer | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2020-01-30 | — | — | US | disclosed |
| US-20170334871-A1 | Thymoquinone Derivatives for Treatment of Cancer | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2017-11-23 | — | — | US | disclosed |
| US-20170334871-A1 | Thymoquinone Derivatives for Treatment of Cancer | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2017-11-23 | — | — | US | disclosed |
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | MERCK SHARP & DOHME CORP. | 2009-08-06 | — | — | US | disclosed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ALDH1A1 2272/4885KDM4E 839/4885GAA 4069/4885 |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | ALDH1A1 3004/4885KDM4E 3841/4885GAA 3461/4885 |
| US-20200031789-A1 | Thymoquinone Derivatives for Treatment of Cancer | TYMS, TYMP, NQO1 | ALDH1A1 324/4885KDM4E 3647/4885GAA 1831/4885 |
| US-20170334871-A1 | Thymoquinone Derivatives for Treatment of Cancer | TYMS, TYMP, NQO1 | ALDH1A1 324/4885KDM4E 3647/4885GAA 1831/4885 |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, ALOX5 | ALDH1A1 347/4885KDM4E 3207/4885GAA 1662/4885 |
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | TH, CYP4X1, CYP4B1 | ALDH1A1 1179/4885KDM4E 217/4885GAA 3827/4885 |
| US-10927088-B2 | Thymoquinone derivatives for treatment of cancer | TYMS, TYMP, NQO1 | ALDH1A1 324/4885KDM4E 3647/4885GAA 1831/4885 |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | ALDH1A1 180/4885KDM4E 222/4885GAA 1531/4885 |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | ALPL, ALPP, ACP3 | ALDH1A1 3056/4885KDM4E 3830/4885GAA 104/4885 |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | ALOX5, LTC4S, ALOX15B | ALDH1A1 362/4885KDM4E 3254/4885GAA 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.